MB 11319

Drug Profile

MB 11319

Alternative Names: MB11319

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator Mazence
  • Developer KT&G Life Sciences
  • Class Anti-inflammatories; Antiallergics; Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hypersensitivity; Prostate cancer; Prostatitis

Most Recent Events

  • 30 Mar 2016 No recent reports on development identified - Phase-I for Hypersensitivity, Prostatitis and Prostate cancer in South Korea (unspecified route)
  • 31 Oct 2013 Phase-I clinical trials in Hypersensitivity, Prostatitis and Prostate cancer in South Korea (unspecified route)
  • 30 Mar 2012 Mazence is now called KT&G Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top